METABOLIC MYOCARDIAL CYTOPROTECTORS IN THERAPY OF STABLE ISCHEMIC HEART DISEASE: EVIDENCE OF EFFECTIVENESS AND USE RECOMMENDATIONS

Abstract

The review describes mechanisms of action of metabolic myocardial cytoprotectors and recommendations on their use within the pharmacotherapy of stable ischemic heart disease. On the basis of results of clinical studies devoted to study of the trimetazidine effectiveness indications of use are specified and a therapeutic niche of this drug in therapy of patients with ischemic heart disease.

Keywords

• ischemic heart disease
• angina
• metabolic myocardial cytoprotectors
• trimetazidine